Macquarie Group
ACER

Macquarie Group’s Acer Therapeutics Inc ACER Stock Holding History

Macquarie Group’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,600
Closed -$36K – 2427
2017
Q4 		$36K Buy
+2,600
New +$42.3K ﹤0.01% 2042

Other funds holding ACER

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Macquarie Group's ACER Position: Q1 2018 in Review

Macquarie Group sold out of Acer Therapeutics Inc (ACER) in Q1 2018, closing a stake of 2,600 shares — an estimated $36K sold.

Macquarie Group first reported a position in ACER in Q4 2017 and held it in 1 quarter. The position peaked at $36K in Q4 2017. 18 funds tracked by Wall St. Rank hold ACER as of Q1 2018.

  • Macquarie Group reported no remaining Acer Therapeutics Inc position as of Q1 2018 after selling out during the quarter.
  • Macquarie Group sold 2,600 Acer Therapeutics Inc shares in Q1 2018, an estimated $36K.
  • Macquarie Group first reported a position in Acer Therapeutics Inc in Q4 2017 and held it in 1 quarter.
  • Macquarie Group's Acer Therapeutics Inc position peaked at $36K in Q4 2017.
  • 18 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.